Tempus Wealth Planning LLC Takes Position in Krystal Biotech, Inc. $KRYS

Key Points

• Tempus Wealth Planning LLC acquired a new position in Krystal Biotech, buying 2,379 shares valued at approximately $327,000 during the second quarter.
• Analyst ratings indicate a consensus of "Moderate Buy" for Krystal Biotech, with price targets ranging from $166.00 to $240.00 across various firms.
• Krystal Biotech's stock has seen a 4.1% increase recently, with its current trading price at $167.82, after reporting a quarterly earnings per share of $1.29, exceeding estimates.

Tempus Wealth Planning LLC purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,379 shares of the company's stock, valued at approximately $327,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. State of Alaska Department of Revenue raised its stake in shares of Krystal Biotech by 7.9% in the second quarter. State of Alaska Department of Revenue now owns 15,130 shares of the company's stock valued at $2,079,000 after buying an additional 1,106 shares during the period. Perigon Wealth Management LLC boosted its position in Krystal Biotech by 4.8% during the second quarter. Perigon Wealth Management LLC now owns 8,898 shares of the company's stock worth $1,223,000 after purchasing an additional 407 shares during the period. Financiere des Professionnels Fonds d investissement inc. purchased a new position in shares of Krystal Biotech in the second quarter worth about $162,000. Parallel Advisors LLC increased its stake in shares of Krystal Biotech by 7.6% in the second quarter. Parallel Advisors LLC now owns 1,863 shares of the company's stock worth $256,000 after purchasing an additional 132 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of Krystal Biotech in the first quarter valued at approximately $1,244,000. 86.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on KRYS shares. Bank of America cut their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Citigroup reiterated a "neutral" rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Chardan Capital dropped their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research report on Monday, September 15th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of "Moderate Buy" and a consensus price target of $209.00.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the completion of the transaction, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 over the last three months. Insiders own 13.70% of the company's stock.

Krystal Biotech Trading Up 4.1%

Shares of NASDAQ KRYS opened at $167.82 on Monday. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $207.84. The firm has a market capitalization of $4.86 billion, a price-to-earnings ratio of 34.11 and a beta of 0.66. The business has a 50-day moving average of $149.49 and a 200-day moving average of $151.18.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.